DK1003545T3 - Heparin-bindende vækstfaktor (HBGF)-polypeptider - Google Patents

Heparin-bindende vækstfaktor (HBGF)-polypeptider

Info

Publication number
DK1003545T3
DK1003545T3 DK98938435T DK98938435T DK1003545T3 DK 1003545 T3 DK1003545 T3 DK 1003545T3 DK 98938435 T DK98938435 T DK 98938435T DK 98938435 T DK98938435 T DK 98938435T DK 1003545 T3 DK1003545 T3 DK 1003545T3
Authority
DK
Denmark
Prior art keywords
polypeptides
hbgf
growth factor
heparin
hbgfs
Prior art date
Application number
DK98938435T
Other languages
Danish (da)
English (en)
Inventor
David A Brigstock
Paul A Harding
Original Assignee
Childrens Hosp Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Res Foundation filed Critical Childrens Hosp Res Foundation
Application granted granted Critical
Publication of DK1003545T3 publication Critical patent/DK1003545T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK98938435T 1997-08-07 1998-08-06 Heparin-bindende vækstfaktor (HBGF)-polypeptider DK1003545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/908,526 US5876730A (en) 1997-08-07 1997-08-07 Heparin-binding growth factor (HBGF) polypeptides
PCT/US1998/016423 WO1999007407A1 (en) 1997-08-07 1998-08-06 Heparin-binding growth factor (hbgf) polypeptides

Publications (1)

Publication Number Publication Date
DK1003545T3 true DK1003545T3 (da) 2008-08-25

Family

ID=25425931

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98938435T DK1003545T3 (da) 1997-08-07 1998-08-06 Heparin-bindende vækstfaktor (HBGF)-polypeptider

Country Status (15)

Country Link
US (3) US5876730A (ja)
EP (1) EP1003545B1 (ja)
JP (2) JP4638027B2 (ja)
CN (1) CN1276729A (ja)
AT (1) ATE395927T1 (ja)
AU (1) AU744585B2 (ja)
BR (1) BR9811861A (ja)
CA (1) CA2299411A1 (ja)
DE (1) DE69839516D1 (ja)
DK (1) DK1003545T3 (ja)
ES (1) ES2307322T3 (ja)
IL (1) IL134330A0 (ja)
NO (1) NO20000579L (ja)
PT (1) PT1003545E (ja)
WO (1) WO1999007407A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
CA2346406C (en) * 1998-10-06 2009-02-17 Anton Wellstein Detection of pleiotrophin
US7141384B1 (en) 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
JP4722290B2 (ja) * 1998-12-14 2011-07-13 ユニバーシティー オブ マイアミ 結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
AU2001288392A1 (en) 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
US7297343B2 (en) * 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
FR2828104B1 (fr) * 2001-08-01 2005-06-24 Chu Montpellier Utilisation d'inhibiteurs du facteur de croissance epidermique liant l'heparine ou d'inhibiteurs de ses recepteurs pour la preparation de medicaments utiles pour traiter le myelome
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
GB0225197D0 (en) * 2002-10-30 2002-12-11 Univ Sheffield Surface
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2005033136A1 (en) * 2003-09-29 2005-04-14 Children's Hospital, Inc. Unique integrin binding site in connective tissue growth factor (ctgf)
CN101884789A (zh) 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
CA2565070A1 (en) 2004-04-28 2005-11-24 Fibrogen, Inc. Anti-ctgf agents for the treatment of pancreatic cancer
DE102004021872B3 (de) 2004-05-04 2005-12-22 Infineon Technologies Ag Chipkarte, Verfahren zum Herstellen einer Chipkarte und elektrisch leitfähiges Kontaktierungselement
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
MX2011002143A (es) 2008-08-25 2011-07-20 Excaliard Pharmaceuticals Inc Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
CN101497656B (zh) * 2009-03-09 2012-08-15 东南大学 与整合素αvβ3具有高结合活性的多肽及其应用
CN102666587A (zh) 2009-07-02 2012-09-12 菲布罗根有限公司 用于治疗肌营养不良的方法
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
MX365647B (es) 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235042A (en) * 1984-02-29 1993-08-10 The Children's Medical Center Corporation Endothelial cell growth factor
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85018A0 (en) * 1988-01-03 1988-06-30 Orgenics Ltd Stable chromogenic substrate mixture of indoxyl phosphate and tetrazolium salt,method of making and using same in biological and diagnostic assays
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
JPH06502538A (ja) 1990-10-16 1994-03-24 ザ　チルドレンズメディカルセンターコーポレーション 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
JPH10502534A (ja) 1994-07-12 1998-03-10 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 結合組織増殖因子−２
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof

Also Published As

Publication number Publication date
AU744585B2 (en) 2002-02-28
US20110160445A1 (en) 2011-06-30
CN1276729A (zh) 2000-12-13
NO20000579L (no) 2000-02-25
AU8696298A (en) 1999-03-01
WO1999007407A1 (en) 1999-02-18
US7897732B2 (en) 2011-03-01
JP4638027B2 (ja) 2011-02-23
BR9811861A (pt) 2000-08-15
JP2009254370A (ja) 2009-11-05
JP2001513334A (ja) 2001-09-04
EP1003545A1 (en) 2000-05-31
US20010007019A1 (en) 2001-07-05
EP1003545B1 (en) 2008-05-21
DE69839516D1 (de) 2008-07-03
CA2299411A1 (en) 1999-02-18
NO20000579D0 (no) 2000-02-04
WO1999007407A9 (en) 1999-05-06
EP1003545A4 (en) 2002-03-06
ATE395927T1 (de) 2008-06-15
PT1003545E (pt) 2008-08-13
ES2307322T3 (es) 2008-11-16
IL134330A0 (en) 2001-04-30
US5876730A (en) 1999-03-02

Similar Documents

Publication Publication Date Title
DK1003545T3 (da) Heparin-bindende vækstfaktor (HBGF)-polypeptider
CY1112101T1 (el) Νευροτροφικοι παραγοντες
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
IL210392A0 (en) Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof
TR200002284T2 (tr) Mage ailesinden tümör ile ilgili tümör türevleri
CY1111750T1 (el) Νευροτροφικοι παραγοντες
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DE59810658D1 (de) Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung desselben
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
PT935652E (pt) Produtos de factor de crescimento de queratinocitos-2
SE9602822D0 (sv) New receptor
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
ATE351909T1 (de) Neue peptidfragmente zur reinigung von proteinen
EA200100110A1 (ru) Нейротрофические факторы
SE9604439D0 (sv) New receptor
WO2001064840A8 (en) Novel bone marrow nucleic acids and polypeptides
DE69832622D1 (de) Methoden zur durchforstung (screenen) von proteinen
TW200635950A (en) Specific binding agents of human angiopoietin-2
NO995804D0 (no) Forbedret fremgangsmåte for fremstilling av lav-konsentrasjons polyaluminosilikatmikrogeler